Clinical trials
Relapsed or Refractory Acute Myeloid Leukemia (AML) clinical trials
Below are recruiting relapsed or refractory acute myeloid leukemia (aml) clinical trials, each written for real people, not researchers. We’re tracking 1,381 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07565428RecruitingPhase 3
Study of roluperidone for negative symptoms of schizophrenia
This trial tests a new medicine called roluperidone for people with schizophrenia who have ongoing negative symptoms (like low motivation or social withdrawal) but stable positive symptoms (like hallucinations). It aims to see if the drug helps with these symptoms and if it can reduce the chance of relapse compared to other medications.
Bellflower, CaliforniaAges 18–55 - NCT07532161Recruiting
Fibrin and Laser Treatment for Gummy Smile Surgery
This study compares two treatment approaches—liquid fibrin (a clotting substance) and soft laser therapy—to help healing and prevent relapse after surgery to reduce a gummy smile caused by an overactive upper lip. The goal is to find which method works better for long-term results.
Damascus, Rif-dimashq GovernorateAges 18–50 - NCT07355972RecruitingEarly Phase 1
CT1195E cell therapy for progressive scleroderma
This trial tests a new cell therapy called CT1195E for people with refractory or progressive systemic sclerosis (scleroderma) that also affects the lungs. It aims to see if the treatment is safe and can help slow or stop the disease.
Wuhan, HubeiAges 18–60 - NCT07070674RecruitingPhase 1
Study of AC-003 for steroid-resistant graft-versus-host disease
This trial tests an experimental capsule (AC-003) for people with graft-versus-host disease (aGVHD) after a stem cell transplant, whose aGVHD did not get better with steroids. The goal is to see if it can help control the condition.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06749990Recruiting
Alcohol relapse risk after liver transplant
This study looks at why some people with alcohol-related liver disease start drinking again after a liver transplant. It aims to find factors that increase or decrease that risk.
BolognaAges 18 years+ - NCT06086197RecruitingPhase 2
A drug combo for early relapsed or refractory DLBCL
This trial tests a combination of chemotherapy drugs for people with a type of lymphoma called diffuse large B-cell lymphoma that has either come back early or never fully responded to first treatment. The goal is to see if this drug combination can help control the lymphoma.
Hangzhou, ZhejiangAges 18 years+ - NCT04518501RecruitingPhase 1/Phase 2
Testing fuzuloparib with arsenic and platinum for ovarian cancer
This early-phase study tests a combination of three medicines to treat ovarian, fallopian tube, or primary peritoneal cancer that has come back after platinum chemotherapy, especially when tumors have a BRCA1 or BRCA2 mutation. The goal is to see if this treatment can help control cancer that is hard to treat.
Zhejiang, HangzhouAges 18–70 - NCT06245434Recruiting
Circadian rhythms during coma awakening
This study looks at how the body's internal clock (circadian rhythm) changes as people wake up from a coma. Researchers hope to learn more about recovery patterns to improve care for patients with brain injuries.
Bron, LyonAges 17 years+ - NCT06630806RecruitingPhase 1
Study of an injection for relapsed or refractory myeloma
This trial tests a new injected drug for people with multiple myeloma that has returned or stopped responding to at least 3 prior treatments. The goal is to see if the drug is safe and works against the cancer.
Phoenix, ArizonaAges 18 years+ - NCT07359014Recruiting
Dual-target car-t cell therapy for multiple myeloma
This trial tests a new type of immunotherapy using your own immune cells (called CAR-T cells) that are modified to attack two targets (CD19 and BCMA) on myeloma cells. It is for patients whose myeloma has come back or stopped responding to standard treatments.
HangzhouAges 18–75 - NCT05869279RecruitingPhase 1/Phase 2
Study of donor immune cells for B-cell blood cancers
This Phase 1/2 study tests an “allogeneic” donor T-cell therapy (CARCIK-CD19) for children and adults with certain B-cell lymphomas and CLL who have tried multiple treatments. It may help by targeting cancer cells using engineered immune cells, but eligibility is complex and depends on donor availability and medical readiness.
Bergamo, BGAges 1 year+ - NCT05568212RecruitingPhase 2
Trial of immune combination versus standard care for NSCLC relapse
This Phase 2 trial studies an immune-based drug combination compared with standard care for lung cancer that has come back after chemoradiation and durvalumab. It aims to improve control of the cancer after durvalumab is no longer working.
Roma, RMAges 18 years+ - NCT07447635Recruiting
Testing a program to help cancer survivors quit smoking and reduce drinking
This study tests a program (MBI) to help cancer survivors quit smoking and cut back on alcohol. It's designed for people who want to make these changes in the next 30 days.
Tampa, FloridaAges 18 years+ - NCT04561206RecruitingPhase 2
Brentuximab plus nivolumab for relapsed Hodgkin lymphoma
This Phase 2 trial studies brentuximab vedotin plus nivolumab in people whose classical Hodgkin lymphoma has come back or did not respond to treatment. It aims to shrink tumors and improve control of the disease, especially when standard options like transplant are not possible.
Duarte, CaliforniaAges 18 years+ - NCT06570447RecruitingPhase 2
Glofitamab and chidamide for relapsed or refractory DLBCL
This trial tests a combination of two drugs, glofitamab and chidamide, for people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded after at least two prior treatments. The goal is to see if this combination can help when other options have stopped working.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06919939RecruitingPhase 2
Epcoritamab and Loncastuximab for relapsed large B-cell lymphoma
This trial tests a combination of two targeted drugs (epcoritamab and loncastuximab tesirine) for people with large B-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if this combination can shrink tumors and improve outcomes.
Miami, FloridaAges 18 years+ - NCT06982443Recruiting
Wellness, alcohol, stress, and emotions study
This trial tests whether wearing a sensor to track your heart rate and emotions can help people with moderate to severe alcohol use disorder reduce drinking. You'll attend group meetings and use a phone or computer for 8 weeks.
Albuquerque, New MexicoAges 18 years+ - NCT05678907Recruiting
Test whether a depression questionnaire predicts relapse after discharge
This study checks whether your answers on a depression questionnaire can predict the chance of depression coming back after you leave the hospital. If it works, it may help doctors spot relapse risk earlier and plan follow-up care.
La Roche-BlancheAges 18 years+ - NCT07058103RecruitingPhase 2
Combination therapy for relapsed or refractory angioimmunoblastic T-cell lymphoma
This trial tests a combination of five drugs (tislelizumab, cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone) for patients with angioimmunoblastic T-cell lymphoma (AITL) that has come back or not responded to previous treatment. The goal is to see if this combination can shrink tumors or stop the disease from growing.
Xuzhou, JiangsuAges 18 years+ - NCT07622277Recruiting
Teeth Alignment Stability After Braces: A Retention Study
This study compares how different face types maintain their bite after orthodontic braces are removed. Researchers will use 3D imaging to track whether teeth stay in their corrected positions during the retention phase (when you wear retainers).
Rohtak, HaryanaAges 18–45 - NCT05934448RecruitingPhase 2
CAR T plus pembrolizumab for relapsed lymphoma after prior treatment
This Phase 2 trial studies CAR T-cell therapy combined with pembrolizumab for certain hard-to-treat lymphomas that have come back or did not respond. It aims to improve tumor response and outcomes after you’ve already tried standard treatments.
Boston, MassachusettsAges 18 years+ - NCT06680050RecruitingPhase 2
Study of radiation plus two drugs for advanced lung cancer after prior treatment
This trial tests whether adding two drugs, durvalumab and ceralasertib, after radiotherapy can help patients with stage III non-small cell lung cancer whose cancer has come back in the chest or spread to a few other spots after previous treatment with durvalumab. It aims to improve outcomes by boosting the immune system's ability to fight the cancer.
BresciaAges 18 years+ - NCT07521683Enrolling by invitationPhase 2
NS-136 treatment study for schizophrenia relapse
This study tests whether NS-136, a new medication, can help people with schizophrenia who are experiencing a relapse or worsening of symptoms. The study measures how well the medication works and what side effects it causes.
ShanghaiAges 18–65 - NCT06822855Recruiting
Improving How We Predict Hodgkin Lymphoma Outcomes
This trial is looking at new ways to predict how Hodgkin lymphoma will respond to treatment. It collects blood and tumor samples at key times to see if these can help doctors make better treatment decisions in the future.
Milan, MIAges 18 years+
Hear when a new Relapsed or Refractory Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory acute myeloid leukemia (aml)?
- Yes. Clin2 currently lists 1,381 recruiting relapsed or refractory acute myeloid leukemia (aml) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory acute myeloid leukemia (aml) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory acute myeloid leukemia (aml) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
- Relapsed/Refractory Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Relapsed Acute Myeloid Leukemia
- Leukemia Acute Myeloid - AML
- Newly Diagnosed Acute Myeloid Leukemia (AML)
- Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.